Continued effort towards the development of isoform-specific, clinically safe PAD inhibitors will, therefore, be imperative to cultivate powerful therapeutic strategies that can take advantage of any therapeutic window that exists between tumour and healthy cells. This evidence concerns the gene PADI4 and neoplasm.